CSI Market
Sign In | Register

Tengjun Biotechnology (CHGH) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CHGH Annual Cash Flow →
Reviewing cash flow figures over time highlights how Tengjun Biotechnology balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2023)
6 Months 		(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Operating Activities
Income-0.08
Depreciation & amortization-0.29
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-1.35
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Allowance For Obselate Inventory-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables-358.24
Increase (Decrease) in Accounts Payable0.22
Increase (Decrease) in Accrued Liabilities2.08
Deferred Revenue and Customer Advances and Deposits385.74
Increase (Decrease) in Prepaid Taxes0.00
Other Working Capital0.00
Other Noncash Income0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities28.08
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment For Construction In Progress-0.11
Cash Receipt From Reverse Merger-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.11
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-6.05
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.37
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Debt Instrument Decrease Forgiveness-
Proceeds Received As Advance For Future Common Stock Subscriptions-
Refundforadvanceforfuturecommonstocksubscription-
Repayment Of Proceeds From Shortterm Bank Loan-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-3.68
Effect of exchange rate on cash flow-2.00
Discontinued operations0.00
Free Cash Flow28.08
Total Cash Flow22.28
4 historic quarters locked

Sign in to unlock the full Tengjun Biotechnology cash flow history.

Sign In Create Free Account

About Tengjun Biotechnology Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-23-067340

Figures are derived from filed reports and may be restated. Historical data is subject to revision.